Immunovant

Valuation Analysis

About the Company

Immunovant en bref

Immunovant (IMVT) is currently trading at 30,84 € with a market capitalization of 6,3 Md €. The 52-week range spans from 12,50 € to 31,66 €; the current price is 2.6% below the yearly high.

💰 Dividende

Immunovant currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

17 analystes évaluent Immunovant (IMVT) au consensus : Acheter. L'objectif de cours moyen est de 39,93 €, soit un potentiel de +29.5% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 20,94 € à 57,60 €.

Immunovant : la thèse d'investissement en détail

Immunovant (IMVT) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Wall Street consensus sits at Buy with an average price target implying roughly 29.5% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Short interest sits at 21.16% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The share is trading at 95.7% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.
• The analyst consensus price target implies 29.5% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (21.16%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Immunovant?

Compare top-rated brokers — low fees, trusted providers, fully regulated.